COVID-19 Ag Rapid Test Device

The COVID-19 Ag Rapid Test Device is a lateral flow rapid diagnostic test used to detect SARS-CoV-2 antigen from respiratory swab specimens. It is designed to identify active infection by detecting viral antigen, especially when viral load is present in the upper respiratory tract. The test may be used with nasopharyngeal swab or nasal swab specimens depending on the product insert.

• The COVID-19 Ag Rapid Test Device helps support fast detection in clinical and screening settings.
• Rapid antigen testing is useful because it provides quick results and can help reduce delay in decision-making.
• This test may support early screening of suspected COVID-19 cases, point-of-care testing, workplace screening, public health surveillance, hospital triage, outbreak response, travel screening, and international diagnostic supply requirements.
• Rapid antigen tests are especially useful when fast turnaround is important, but results should be interpreted carefully because antigen tests may be less sensitive than molecular PCR tests in some situations.

The COVID-19 Ag Rapid Test Device by LARKSOIS Pharma may be used in professional diagnostic and healthcare screening environments.

Applications

• Suspected COVID-19 case screening
• Hospitals and clinical laboratories
• Diagnostic centers and clinics
• Point-of-care testing workflows
• Workplace and institutional screening
• Public health monitoring
• Travel and event-related screening programs
• Rapid outbreak response
• International diagnostic distribution

• The COVID-19 Ag Rapid Test Device works on an immunochromatographic lateral flow principle.
• After sample extraction, the processed specimen is added to the sample well according to the product insert.
• If SARS-CoV-2 antigen is present at or above the detection level, it reacts with specific antibodies on the test membrane and forms a visible test line.
• A control line appears to confirm valid sample flow and proper test performance. The result should always be read according to the official LARKSOIS Pharma product insert.

The COVID-19 Ag Rapid Test Device uses rapid lateral flow immunochromatographic technology for qualitative detection of SARS-CoV-2 antigen from nasopharyngeal or nasal swab specimens.

Benefits

• Rapid qualitative detection of SARS-CoV-2 antigen
• Suitable for nasopharyngeal and nasal swab specimens
• Simple visual result interpretation
• No major instrument required
• Supports point-of-care screening workflows
• Useful for hospitals, clinics, diagnostic centers, and public health programs
• Designed for professional in-vitro diagnostic use
• Suitable for international diagnostic supply

The COVID-19 Ag Rapid Test Device is designed for nasopharyngeal swab or nasal swab specimens. Correct specimen collection and handling are important for reliable screening performance.

Guidance

• Use approved respiratory swab specimens only
• Collect nasopharyngeal or nasal swab specimens according to the product insert
• Use clean and suitable swab collection materials
• Avoid contaminated or improperly stored samples
• Process the swab using the provided extraction buffer as instructed
• Apply the extracted specimen to the test device correctly
• Read results only within the recommended time window
• Treat all specimens as potentially infectious material

Note

Specimen collection, extraction, timing, and storage should always follow the official LARKSOIS Pharma kit insert.

The COVID-19 Ag Rapid Test Device by LARKSOIS Pharma has a stated cut-off of 100 TCID/ml. This means the test is designed to detect SARS-CoV-2 antigen at or above the validated detection level. LARKSOIS Pharma should publish exact performance details according to the final product insert, technical file, and regulatory documentation.

• COVID-19 antigen testing can support fast screening where immediate preliminary results are useful.
• A positive result suggests SARS-CoV-2 antigen may be present in the tested specimen and should be interpreted with symptoms, exposure history, and local healthcare guidance.
• A negative result does not completely rule out COVID-19, especially if testing is done too early, too late, or if specimen quality is poor.
• Healthcare professionals should interpret results with clinical condition, exposure risk, and additional testing where required.

The COVID-19 Ag Rapid Test Device is intended as a qualitative screening aid and should not be used as the only basis for diagnosis, treatment, isolation, or public health decisions.

Instructions

• A positive result suggests SARS-CoV-2 antigen detection but does not confirm disease severity
• A negative result does not always rule out COVID-19 infection
• Testing too early or too late in infection may affect antigen detection
• Improper specimen collection may affect results
• Low viral load may produce a negative result
• Expired or poorly stored kits may affect performance
• Results should be interpreted with symptoms, exposure history, and local healthcare guidance
• Molecular testing may be required depending on clinical condition and local guidelines

Instructions

• Rapid qualitative detection of SARS-CoV-2 antigen
• Suitable for nasopharyngeal and nasal swab specimens
• Simple visual result interpretation
• No major instrument required
• Supports point-of-care screening workflows
• Useful for hospitals, clinics, diagnostic centers, and public health programs
• Designed for professional in-vitro diagnostic use
• Suitable for international diagnostic supply

Note

The COVID-19 Ag Rapid Test Device by LARKSOIS Pharma is developed for professional users who need fast and practical infectious disease screening support.

Steps

• Bring the test device, specimen, and extraction buffer to the recommended testing condition if required
• Open the sealed pouch only when ready to test
• Collect the nasopharyngeal or nasal swab specimen according to the product insert
• Place the swab into the extraction buffer and process as instructed
• Apply the extracted specimen to the sample well of the test device
• Wait for the test reaction to complete within the stated time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the COVID-19 Ag Rapid Test Device.

Positive

A positive result usually shows both the control line and test line. This suggests that SARS-CoV-2 antigen may be present in the specimen. The result should be interpreted with symptoms, exposure history, and healthcare guidance.

Negative

A negative result usually shows the control line only. This suggests that SARS-CoV-2 antigen was not detected or was below the test detection level at the time of testing. A negative result does not completely rule out COVID-19.

Invalid

If the control line does not appear, the result is invalid. The test should be repeated with a new device and properly collected specimen according to the product insert.

Instructions

• Store the test device according to the product label instructions
• Keep the test sealed until use
• Protect from moisture
• Avoid direct sunlight and extreme temperatures
• Do not use expired or damaged test kits
• Use only approved swabs and extraction materials
• Read results within the recommended time window
• Follow the storage temperature mentioned on the product label

Instructions

• For professional in-vitro diagnostic use only
• Use approved respiratory swab specimens only
• Do not reuse the test device
• Do not use damaged or expired kits
• Handle all specimens as potentially infectious material
• Follow biosafety and disposal procedures
• Read results only within the recommended time window
• Negative results do not fully rule out COVID-19
• Follow local healthcare and public health guidance

LARKSOIS Pharma provides international-quality diagnostic and healthcare products for hospitals, laboratories, clinics, distributors, and public health programs. The COVID-19 Ag Rapid Test Device is developed for fast infectious disease screening, practical workflow integration, and dependable global diagnostic supply.

Advantages

• International diagnostic product focus
• Reliable rapid testing solutions
• Suitable for hospitals, clinics, and laboratories
• Distributor-friendly product format
• Supports infectious disease screening workflows
• Practical swab-based testing format
• Quality-focused standards under LARKSOIS Pharma